Australia issues patent for Kane’s DispersinB

Kane Biotech (TSXV:KNE) received patent protection in Australia for its DispersinB anti-biofilm technology, the third country to cover the technology.

The patent claims the gene encoding DispersinB enzyme and also the amino acid sequence of the enzyme, as well as method of production, pharmaceutical composition, methods of administration and applications in medical devices.

Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

“We are very pleased that our DispersinB patents are beginning to issue around the world and we now have patent protection in the United States, New Zealand and Australia, with pending patents in other countries as well”, CEO Gord Froehlich said in a statement.